↓ Skip to main content

Dove Medical Press

Article Metrics

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

Overview of attention for article published in International Journal of Nanomedicine, April 2015
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
38 Mendeley
Title
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
Published in
International Journal of Nanomedicine, April 2015
DOI 10.2147/ijn.s75962
Pubmed ID
Authors

Caroline J Sheeba, Gregory Marslin, Ann Mary Revina, Vinoth Khandelwal, Krishnamoorthy Balakumar, Jose Prakash, Gregory Franklin

Abstract

Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could sustainably release the drug, and studied its efficacy by in vitro anticancer and in vivo cardiotoxicity assays. MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay revealed that INPs are more cytotoxic to MCF-7 breast cancer cells compared to the equivalent concentration of free imatinib mesylate. Wistar rats orally administered with 50 mg/kg INPs for 28 days showed no significant cardiotoxicity or associated changes. Whereas, increased alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels, and reduced white blood cell, red blood cell, and hemoglobin content were observed in the animals administered with free drug. While the histological sections from hearts of animals that received INPs did not show any significant cardiotoxic symptoms, loss of normal architecture and increased cytoplasmic vacuolization were observed in the heart sections of animals administered with free imatinib mesylate. Based on these results, we conclude that nano-encapsulation of imatinib mesylate increases its efficacy against cancer cells, with almost no cardiotoxicity.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 3%
Unknown 37 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 24%
Student > Master 6 16%
Researcher 4 11%
Student > Bachelor 3 8%
Professor > Associate Professor 3 8%
Other 6 16%
Unknown 7 18%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 11 29%
Agricultural and Biological Sciences 3 8%
Medicine and Dentistry 3 8%
Chemistry 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Other 7 18%
Unknown 10 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2015.
All research outputs
#4,293,055
of 5,163,159 outputs
Outputs from International Journal of Nanomedicine
#1,141
of 1,366 outputs
Outputs of similar age
#147,122
of 184,056 outputs
Outputs of similar age from International Journal of Nanomedicine
#146
of 155 outputs
Altmetric has tracked 5,163,159 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,366 research outputs from this source. They receive a mean Attention Score of 1.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,056 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.